How Will the Cancer Tumor Profiling Market Grow? Key Trends and Opportunities for 2025 and Beyond
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the cancer tumor profiling market grown over the years?
The market size for cancer tumor profiling has seen a quick expansion in the last few years. It is projected to increase from $13 billion in 2024 to $14.99 billion in 2025, with a compound annual growth rate (CAGR) of 15.3%. The noteworthy growth in the past period is tied to factors such as the rise in the cases of cancer, expansion in precision medicine initiatives and research partnerships, enhancements in cancer diagnosis and methods for early detection, the availability of numerous targeted therapy alternatives, and positive governmental regulations pertaining to cancer profiling tests.
What Is the forecasted market size and growth rate for the cancer tumor profiling market?
In the coming years, the market size for cancer tumor profiling is projected to experience significant growth, reaching $25.33 billion by 2029 with a compound annual growth rate (CAGR) of 14.0%. This growth within the anticipated period is largely due to the expansion of immunotherapy and immunoprofiling in the treatment of cancer, advancements in liquid biopsy and non-invasive profiling of tumors, the usage of single-cell sequencing for more intricate tumor characterization, broadening of cancer screening and early detection programs, and a higher demand for rare and orphan cancer subtype profiling. Key trends over the forecast period consist of incorporating tumor profiling into regular clinical practice, progress in multi-omics approaches, the incorporation of artificial intelligence (AI) and machine learning for data analysis, personalized medicine and development of targeted treatments, and advances in the field of genomics and next-generation sequencing (NGS) technologies.
Get your cancer tumor profiling market report here!
https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report
What are the major factors driving growth in the cancer tumor profiling market?
In the coming years, the market size for cancer tumor profiling is projected to experience significant growth, reaching $25.33 billion by 2029 with a compound annual growth rate (CAGR) of 14.0%. This growth within the anticipated period is largely due to the expansion of immunotherapy and immunoprofiling in the treatment of cancer, advancements in liquid biopsy and non-invasive profiling of tumors, the usage of single-cell sequencing for more intricate tumor characterization, broadening of cancer screening and early detection programs, and a higher demand for rare and orphan cancer subtype profiling. Key trends over the forecast period consist of incorporating tumor profiling into regular clinical practice, progress in multi-omics approaches, the incorporation of artificial intelligence (AI) and machine learning for data analysis, personalized medicine and development of targeted treatments, and advances in the field of genomics and next-generation sequencing (NGS) technologies.
What key areas define the segmentation of the global cancer tumor profiling Market?
The cancer tumor profiling market covered in this report is segmented –
1) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Other Cancer Types
2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Other Technologies
3) By Process Type: Genomics, Proteomics, Epigenetics, Metabolomics, Other Types
4) By Application: Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications
Subsegments:
1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
2) By Breast Cancer: Hormone Receptor-Positive, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer
3) By Colorectal Cancer: Colon Cancer, Rectal Cancer
4) By Prostate Cancer: Localized Prostate Cancer, Advanced Prostate Cancer
5) By Melanoma: Cutaneous Melanoma, Non-Cutaneous Melanoma
6) By Ovarian Cancer: Epithelial Ovarian Cancer, Non-Epithelial Ovarian Cancer
7) By Stomach Cancer: Gastric Adenocarcinoma, Gastrointestinal Stromal Tumors (GISTs)
8) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Neuroendocrine Tumors
9) By Thyroid Cancer: Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer
10) By Other Cancer Types: Kidney Cancer, Bladder Cancer, Liver Cancer, Esophageal Cancer
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp
What are the top market players propelling the growth of the cancer tumor profiling industry?
Major companies operating in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, Genomic Testing Cooperative, OncoDNA, Strata Oncology Inc., Genuity Science, RareCyte Inc., Inivata Limited, Cepheid
What are the key trends shaping the future of the cancer tumor profiling market?
A significant emerging trend in the cancer and tumor profiling market is the escalating focus on research and development activities. This trend is particularly popular among major firms in the sector, who are concentrating their efforts on these activities as a means of satisfying customer needs and strengthening their market position. A case in point is QIAGEN N.V., a German business specializing in the development of sample and assay technology for a range of uses, including applied testing, pharmaceutical development, molecular diagnostics, and academic research. To further underline this emerging trend, QIAGEN N.V. recently announced the CE-marking and subsequent commercialization of their therascreen PIK3CA RGQ PCR Kit in Europe. This tool seeks to aid in the identification of breast cancer patients with PIK3CA mutations. The therascreen PIK3CA test, not only detects an activating mutation in the phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) gene, but it is also the first of its kind to permit the testing of both DNA from plasma specimens or FFPE tissue.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6053
What regions are dominating the cancer tumor profiling market growth?
North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Cancer Clinical Decision Tools Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cancer-clinical-decision-tool-global-market-report
Tumor Ablation Therapy Devices Global Market Report 2024
Cancer Diagnostics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
